Entera Bio Ltd., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of orally delivered large molecule therapeutics for unmet medical needs. The company's lead product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of non-union fractures. The company has a research collaboration and license agreement with the Amgen Inc. for the development and discovery of clinical candidates in the field of inflammatory disease and other serious illnesses. Entera Bio Ltd. was incorporated in 2009 and is based in Jerusalem, Israel.

CEO

Ms. Miranda J. Toledano M.B.A.

Employees

Country

Israel

ISIN

IL0011429839

Listings

0 Comments

Share your thoughts

FAQ

What is Entera Bio stock price today?▼

The current price of 5DT.STU is €1.03 EUR — it has increased by +7.29% in the past 24 hours. Watch Entera Bio stock price performance more closely on the chart.

What is Entera Bio stock ticker?▼

Depending on the exchange, the stock ticker may vary. For instance, on exchange Entera Bio stocks are traded under the ticker 5DT.STU.

Is Entera Bio stock price growing?▼

5DT.STU stock has risen by +8.99% compared to the previous week, the month change is a -4.1% fall, over the last year Entera Bio has showed a -44.98% decrease.

When is the next Entera Bio earnings date?▼

Entera Bio is going to release the next earnings report on May 08, 2026.

How many employees does Entera Bio have?▼

As of May 06, 2026, the company has 18 employees.

In which sector is Entera Bio located?▼

Entera Bio operates in the Health & Wellness sector.

When did Entera Bio complete a stock split?▼

Entera Bio has not had any recent stock splits.

Where is Entera Bio headquartered?▼

Entera Bio is headquartered in Jerusalem, Israel.